-
淋巴瘤是起源于人类免疫系统细胞及其前体细胞的恶性增殖性疾病,每年新发病例约20 000例,年平均病死率约为1.46/10万,位居全国恶性肿瘤的第11位[1]。淋巴瘤可分为霍奇金淋巴瘤(Hodgkin lymphoma,HL)和非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)。在我国,HL占全部恶性淋巴瘤的10.9%,约90%首先表现为淋巴结肿大,通常呈对称性淋巴结肿大,很少累及结外组织。HL对放疗、化疗很敏感,是可治愈的肿瘤之一,其5年无病生存率(event-free survival,EFS)约为80%。目前对于HL的诊断、分期及治疗的评估主要依靠影像学检查,如超声检查(ultrasonography,US)、CT、MRI、67Ga肿瘤显像、PET/CT等。CT、MRI已成为现今用于评价淋巴瘤分期、治疗效果的最常用的显像技术之一。18F-FDG PET/CT以其灵敏度高、特异性强、准确性好的优点越来越广泛地应用于恶性淋巴瘤的临床实践,并对肿瘤的诊断和分期、疗效评估、预后判断具有重要的临床价值。
影像学技术在霍奇金淋巴瘤诊疗中的价值
The value of medical imaging methods in diagnosis and treatment of Hodgkin lymphoma
-
摘要: 在我国,霍奇金淋巴瘤(HL)占全部恶性淋巴瘤的10.9%,约90%起源于淋巴结,通常呈对称性淋巴结肿大,很少累及结外组织。HL对放疗、化疗很敏感,是可治愈的肿瘤之一。该文主要就CT成像、MRI、67Ga成像、PET或PET/CT在HL诊断及预后评估等方面的应用作一综述,以进一步提高对HL影像学表现及其临床应用的认识。
-
关键词:
- 淋巴瘤,霍奇金 /
- 体层摄影术,X线计算机 /
- 磁共振成像 /
- 正电子发射断层显像术
Abstract: Hodgkin lymphoma(HL)accounts for 10.9% of all malignant lymphoma in China.About 90% of HL originates from the lymph nodes. The involved lymph nodes are usually symmetrical. HL seldom involves extranodal tissues. HL is one of the curable tumors and sensitive to chemotherapy and radiotherapy. This article aims to improving the knowledge of the value of medical imaging methods in diagnosis and treatment of HL by reviewing the present state of CT, MRI, 67Ga and PET or PET/CT in imaging of HL. -
[1] Roman E, Smith AG. Epidemiology of lymphomas[J]. Histopathology, 2011, 58(1): 4-14. [2] 白人驹, 张雪林.医学影像诊断学[M]. 3版.北京:人民卫生出版社, 2010: 6-10.
[3] Cabanillas F, Fuller LM. The radiologic assessment of the lymphoma patient from the standpoint of the clinician[J]. Radiol Clin North Am, 1990, 28(4): 683-695. [4] Enhert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial[J]. J Clin Oncol, 2007, 25(23): 3495-3502. doi: 10.1200/JCO.2006.07.0482 [5] Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatmentof patients with advanced Hodgkin′s lymphoma: results from the HD2000 Group Italiano per lo Studio dei Linfomi Trial[J]. J Clin Oncol, 2009, 27(5): 805-811. doi: 10.1200/JCO.2008.17.0910 [6] Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin′s lymphoma[J]. N Engl J Med, 2010, 363(7): 640-652. doi: 10.1056/NEJMoa1000067 [7] 李琼, 白人驹, 孙浩然, 等. MR DWI在淋巴瘤检出、疗效监测中的应用[J].中国医学影像技术, 2010, 26(12): 2313-2316.
[8] Mürtz P, Krautmacher C, Träber F, et al. Diffusion- weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 tesla[J]. Eur Radiol, 2007, 17(12): 3031-3037. doi: 10.1007/s00330-007-0717-8 [9] Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging[J]. J Nucl Med, 2004, 45(9): 1509-1518. [10] Komori T, Narabayashi I, Matsumura K, et al. 2-[Fluorine-18]-fluoro -2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience[J]. Ann Nucl Med, 2007, 21(4): 209-215. doi: 10.1007/s12149-007-0010-6 [11] Punwani S, Taylor SA, Bainbridge A, et al. Pediatric and adolescent lymphoma: comparison of whole-Body STIR Half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging[J]. Radiology, 2010, 255(1): 182-190. doi: 10.1148/radiol.09091105 [12] Okada M, Sato N, Ishii K, et al. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma[J]. Radiographics, 2010, 30(4): 939-957. doi: 10.1148/rg.304095150 [13] Rahmouni A, Luciani A, Itti E. MRI and PET in monitoring response in lymphoma[J/OL]. Cancer Imaging, 2005, 5: 106-112[2013-05-19]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1665309. [14] Toh CH, Castillo M, Wong AM, et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging[J]. AJNR Am J Neuroradiol, 2008, 29(3): 471-475. doi: 10.3174/ajnr.A0872 [15] Chun CW, Jee WH, Park HJ, et al. MRI features of skeletal muscle lymphoma[J]. AJR Am J Roentgenol, 2010, 195(6): 1355-1360. doi: 10.2214/AJR.09.3904 [16] Politi LS, Forghani R, Godi C, et al. Ocular adnexal lymphoma: diffusion-weighted MR imaging for differential diagnosis and therapeutic monitoring[J]. Radiology, 2010, 256(2): 565-574. [17] 胡兴荣, 冉瑞智, 张家权, 等.全身扩散加权成像在恶性淋巴瘤诊断中的价值[J].放射学实践, 2010, 25(8): 892-895.
[18] Kostakoglu L, Leonard JP, Kuji I, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma[J]. Cancer, 2002, 94(4): 879-888. doi: 10.1002/cncr.10336 [19] Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison[J]. Leuk Lymphoma, 2004, 45(1): 85-92. [20] Connors JM. Positron emission tomography in the management of hodgkin lymphoma[J/OL]. Am Soc Hematol Educ Program, 2011, 2011: 317-322[2013-05-19]. http://www.ncbi.nlm.nih.gov/pubmed/22160052. [21] Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma[J]. J Clin Oncol, 2007, 25(5): 571-578. doi: 10.1200/JCO.2006.08.2305 [22] Picardi M, Soricelli A, Grimaldi F, et al. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin′s lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen[J]. Ann Oncol, 2011, 22(3): 671-680. doi: 10.1093/annonc/mdq403 [23] 马林峰, 樊卫.淋巴瘤病灶对18F-FDG摄取与不同病理亚型的关系[J].癌症, 2009, 28(4): 425-430.
[24] Pelosi E, Penna D, Deandreis D, et al. FDG-PET in the detection of bone marrow disease in Hodgkin′s disease and aggressive non-Hodgkin′s lymphoma and its impact on clinical management[J]. Q J Nucl Med Mol Imaging, 2008, 52(1): 9-16. [25] 吴维颢, 程志祥, 王伟光, 等. 56例霍奇金淋巴瘤的回顾性分析[J].临床血液学杂志, 2012, 25(3): 140-143.
[26] Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma[J]. J Nucl Med, 2009, 50 Suppl 1: 21S-30. [27] Straus DJ, Johnson JL, LaCasce AS, et al. Doxorubicin, vinblastine, and gemcitabine(CALGB 50203) for stage Ⅰ/Ⅱ nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET[J]. Blood, 2011, 117(20): 5314-5320. doi: 10.1182/blood-2010-10-314260 [28] Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin′s lymphoma[J]. Ann Oncol, 2011, 22(4): 910-915. doi: 10.1093/annonc/mdq549 [29] Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin′s lymphoma[J]. Ann Oncol, 2010, 21(1): 126-132. doi: 10.1093/annonc/mdp271 [30] Markova J, Kobe C, Skopalova M, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin′s lymphoma has a high negative predictive value[J]. Ann Oncol, 2009, 20(7): 1270-1274. doi: 10.1093/annonc/mdn768 [31] Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin′s lymphoma: a report from a joint italian-danish study[J]. J Clin Oncol, 2007, 25(24): 3746-3752. doi: 10.1200/JCO.2007.11.6525 [32] Barnes JA, LaCasce AS, Zukotynski K, et al. End of treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin′s lymphoma[J]. Ann Oncol, 2011, 22(4): 910-915. doi: 10.1093/annonc/mdq549 [33] Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin′s lymphomas. NCI Sponsored International Working Group[J]. J Clin Oncol, 1999, 17(4): 1244. doi: 10.1200/JCO.1999.17.4.1244 [34] Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol, 2007, 25(5): 579-586. doi: 10.1200/JCO.2006.09.2403 [35] Re A, Ferrari S, Frata P, et al. Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin′s lymphoma. A prospective phase Ⅱ study[J]. Ann Oncol, 2008, 19(5): 951-957. doi: 10.1093/annonc/mdm596 [36] Mocikova H, Obrtlikova P, Vackova B, et al. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study[J]. Ann Oncol, 2010, 21(6): 1222-1227. doi: 10.1093/annonc/mdp522 [37] 龚红霞, 路青, 朱炯, 等. 3.0T磁共振弥散加权成像和表观弥散系数在淋巴瘤诊断中的价值[J].上海交通大学学报:医学版, 2008, 28(8): 944-947.
[38] Engert A, Kobe C, Markova J, et al. Assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin lymphoma after completion of chemotherapy: Final report of the GHSG HL15 trial[J]. Blood(ASH Annual Meeting Abstracts), 2010, 116(21): 336. [39] Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma[J]. Blood, 2008, 112(10): 3989-3994. doi: 10.1182/blood-2008-06-155820 [40] Sher DJ, Mauch PM, Van Den Abbeele A, et al. Prognostic significance of mid-and post-ABVD PET imaging in Hodgkin′s lymphoma: the importance of involved-field radiotherapy[J]. Ann Oncol, 2009, 20(11): 1848-1853. doi: 10.1093/annonc/mdp071 [41] Schaefer NG, Taverna C, Strobel K, et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy-is biopsy of FDG-avid lesions still needed?[J]. Radiology, 2007, 244(1): 257-262. doi: 10.1148/radiol.2441060810 [42] Zanoni L, Cerci JJ, Fanti S. Use of PET/CT to evaluate response to therapy in lymphoma[J]. Q J Nucl Med Mol imaging, 2011, 55(6): 633-647. [43] Sonoda LI, Sanghera B, Wong WL. Investigation of dose minimisation protocol for 18F-FDG PET-CT in the management of lymphoma postchemotherapy followup[J/OL]. Sci World J, 2012, 2012: 208135[2014-05-20]. http://www.hindawi.com/journals/tswj/2012/208135. [44] Petrausch U, Samaras P, Veit-Haibach P, et al. Hodgkin′s lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?[J]. Ann Oncol, 2010, 21(5): 1053-1057. doi: 10.1093/annonc/mdp519 [45] Lee AI, Zuckerman DS, Van den Abbeele AD, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis[J]. Cancer, 2010, 116(16): 3835-3842. doi: 10.1002/cncr.25240 [46] Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma[J]. Haematologica, 2007, 92(6): 771-777. doi: 10.3324/haematol.10798 [47] El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs[J]. Haematologica, 2012, 97(6): 931-936. doi: 10.3324/haematol.2011.056010 [48] Rademaker J, Schoder H, Ariaratnam NS, et al. Coronary artery disease after radiation therapy for Hodgkin′s lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients[J]. AJR Am J Roentgenol, 2008, 191(1): 32-37. doi: 10.2214/AJR.07.3112 [49] Cole PD, McCarten KM, Drachtman RA, et al. Early FDG-PET-based Response Evaluation After Treatment with Gemcitabine and Vinorelbine for Refractory Hodgkin Disease: A Children′s Oncology Group Report[J]. Pediatr Hematol Oncol, 2010, 27(8): 650-657. doi: 10.3109/08880018.2010.504250 [50] Dodero A, Crocchiolo R, Patriarca F, et al. Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation[J]. Cancer, 2010, 116(21): 5001-5011. doi: 10.1002/cncr.25357 [51] Ghai S, Pattison J, Ghai S, et al. Primary gastrointestinal lymphoma: spectrum of imaging findings with pathologic correlation[J]. Radiographics, 2007, 27(5): 1371-1388. doi: 10.1148/rg.275065151 [52] Huang MQ, Nelson DS, Pickup S, et al. In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS[J]. Acad Radiol, 2007, 14(12): 1531-1539. doi: 10.1016/j.acra.2007.07.012 [53] Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistoehemistry in non-small cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2007, 34(10): 1610-1616. doi: 10.1007/s00259-007-0449-7 [54] Troost EG, Vogel WV, Merkx MA, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients[J]. J Nucl Med, 2007, 48(5): 726-735. doi: 10.2967/jnumed.106.037473 [55] Lawrence J, Vanderhoek M, Barbee D, et al. Use of 3'-deoxy-3'[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin′s lymphoma[J]. Vet Radiol U1trasound, 2009, 50(6): 660-668. doi: 10.1111/j.1740-8261.2009.01612.x [56] Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma[J]. Cancer Res, 2006, 66(22): 11055-11061. doi: 10.1158/0008-5472.CAN-06-1955 [57] 王瑞民, 朱海燕, 李菲, 等. 18F-FLT PET/CT在弥漫大B细胞淋巴瘤诊断及分期中的价值[J].中国实验血液学杂志, 2012, 20(3): 603-607.
[58] Herrmann K, Buck AK, Schuster T, et al. Predictive Value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment[J]. J Nucl Med, 2011, 52(5): 690-696. doi: 10.2967/jnumed.110.084566
计量
- 文章访问数: 3237
- HTML全文浏览量: 2149
- PDF下载量: 8